When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.
A new analysis has determined potential risk factors for developing myasthenia gravis following COVID-19 vaccination, with symptoms likely to appear within 2 weeks of receipt of a COVID-19 vaccine.